Dong-hua H. Luo

651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Retraction: Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway.

Retraction: Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway.

Journal: Oncotarget

Published: May 26, 2026

Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial.

Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial.

Journal: Nature communications

Published: October 15, 2025

Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma.

Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma.

Journal: British journal of cancer

Published: August 05, 2025

Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.

Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: June 18, 2025

Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial.

Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trial.

Journal: EClinicalMedicine

Published: June 05, 2025

Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.

Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.

Journal: NEJM evidence

Published: April 22, 2025

Application of multidimensional diffusion-weighted magnetic resonance imaging in nasopharyngeal carcinoma: a prospective study.

Application of multidimensional diffusion-weighted magnetic resonance imaging in nasopharyngeal carcinoma: a prospective study.

Journal: Clinical radiology

Published: March 30, 2025

Prevalence of mental disorders and their associations with age at diagnosis and time since diagnosis of nasopharyngeal cancer.

Prevalence of mental disorders and their associations with age at diagnosis and time since diagnosis of nasopharyngeal cancer.

Journal: Frontiers in public health

Published: July 23, 2024

Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma.

Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma.

Journal: Cell reports. Medicine

Published: July 01, 2024

Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.

Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.

Journal: The Lancet. Oncology

Published: June 18, 2024

Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of Prostate cancer

Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of Prostate cancer

Journal: Zhonghua yi xue za zhi

Published: April 21, 2024

Individualised cumulative cisplatin dose for locoregionally advanced nasopharyngeal carcinoma patients based on induction chemotherapy response and tumour volume.

Individualised cumulative cisplatin dose for locoregionally advanced nasopharyngeal carcinoma patients based on induction chemotherapy response and tumour volume.

Journal: Therapeutic advances in medical oncology

Published: February 17, 2024

Showing 1-12 of 95

Last Updated: 09/26/2026